Drug-Receptor Interactions and Dose-Response

Receptors & Ligands - Pharma's First Date

• Receptor: Cellular macromolecule where drugs bind to initiate effects.

  • Major Types:
    • Ligand-gated ion channels (Ionotropic): Rapid; e.g., nAChR.
    • G-protein coupled (GPCR/Metabotropic): Common; e.g., Adrenergic R.
    • Enzyme-linked: e.g., Insulin R.
    • Nuclear/Intracellular: Slowest; e.g., Steroid R.

• Ligand: Molecule binding to a receptor.

  • Agonist: Binds & activates.
    • Full: Max effect ($E_{max}$).
    • Partial: Submaximal $E_{max}$; may antagonize full agonist.
    • Inverse: Opposite effect to agonist.
  • Antagonist: Binds & blocks; no intrinsic activity.
    • Competitive: Reversible; ↑ apparent $K_D$ of agonist.
    • Non-competitive: Irreversible/allosteric; ↓ $E_{max}$.

⭐ GPCRs are the largest receptor family, targeted by ~30-40% of modern drugs.

Drug-Receptor Dynamics - The Binding Story

• Drug ($D$) + Receptor ($R$) $\rightleftharpoons$ Drug-Receptor Complex ($DR$) $\rightarrow$ Response.
• Binding: Reversible, follows Law of Mass Action.
• Affinity: Tendency to bind receptor.
  • Measure: $K_D$ (dissociation constant).
  • $K_D = \frac{[D][R]}{[DR]}$
  • ↓ $K_D$ = ↑ Affinity. $K_D$: [Drug] for 50% receptor occupancy.
• Efficacy (Intrinsic Activity): Ability to activate receptor after binding.
  • Agonist: Affinity + Efficacy (e.g., Morphine).
  • Antagonist: Affinity + Zero Efficacy (e.g., Naloxone).
  • Partial Agonist: Affinity + Submaximal Efficacy.
  • Inverse Agonist: Affinity + Negative Efficacy.
• Potency: Drug amount for a specific effect (e.g., $EC_{50}$ for 50% max effect).
  • ↓ $EC_{50}$ = ↑ Potency.
  • Reflects affinity & efficacy.

⭐ Antagonists possess affinity but have zero intrinsic activity (efficacy = 0). They do not produce a response on their own but block the action of agonists.

Dose-Response Curves - Curve Appeal

• Visualizes drug effect vs. dose/concentration.
• Graded DRC:
  • Individual response; continuous effect.
  • Log dose-response: Sigmoidal curve.
  • Parameters:
    • $E_{max}$: Maximum effect (Efficacy). ↑$E_{max}$ = ↑efficacy.
    • $EC_{50}$: Concentration for 50% $E_{max}$ (Potency). ↓$EC_{50}$ = ↑potency.
    • 📌 Potency = Position ($EC_{50}$); Efficacy = Elevation ($E_{max}$).
• Quantal DRC:
  • Population response; all-or-none (e.g., cure, death).
  • Parameters:
    • $ED_{50}$: Dose effective in 50% population.
    • $LD_{50}$: Dose lethal in 50% population.
    • Therapeutic Index (TI): $LD_{50} / ED_{50}$. ↑TI = safer drug.
• Slope: Steep slope = small dose change, large response change.

⭐ Therapeutic Index (TI) is a measure of drug safety; a higher TI indicates a safer drug, representing a wider margin between effective and toxic doses.

Antagonism & Therapeutic Index - Block & Balance

• Antagonism: Process where one drug ↓ or prevents action of another.
  • Competitive Antagonism:
    • Binds agonist's receptor site.
    • Reversible: Shifts Dose-Response Curve (DRC) right (↑ED₅₀), Eₘₐₓ unchanged. Surmountable by ↑agonist dose.
    • Irreversible: Binds covalently. ↓Eₘₐₓ, not surmountable.
  • Non-competitive Antagonism:
    • Binds to allosteric site or different receptor. ↓Eₘₐₓ. Not surmountable.
  • Physiological (Functional): Two drugs, opposite effects via different receptors (e.g., histamine & adrenaline).
  • Chemical: Direct drug interaction (e.g., chelating agents with heavy metals).
• Therapeutic Index (TI) & Safety:
  • TI: Measure of drug safety. $TI = \frac{TD_{50}}{ED_{50}}$ (Median Toxic Dose / Median Effective Dose).
    • ↑TI = Safer drug.
    • ⭐ > Drugs with low TI (e.g., Warfarin, Digoxin, Lithium, Phenytoin, Theophylline) require close monitoring. 📌 Remember: "Little Therapeutic Index Drugs Worry Physicians" (Lithium, Theophylline, Digoxin, Warfarin, Phenytoin).
  • Therapeutic Window: Dose range between Minimum Effective Concentration (MEC) & Minimum Toxic Concentration (MTC).
  • Certain Safety Factor (CSF): $CSF = \frac{LD_1}{ED_{99}}$. A more stringent safety index.

High‑Yield Points - ⚡ Biggest Takeaways

• Receptors are macromolecular targets for drugs, primarily proteins.
• Affinity (Kd) measures drug-receptor binding strength; lower Kd means higher affinity.
• Efficacy (Emax) is the maximal response a drug can produce.
• Potency (ED50/EC50) is the dose/concentration producing 50% of maximal effect.
• Agonists have affinity and efficacy; antagonists have affinity but no efficacy.
• Competitive antagonists shift Dose-Response Curve (DRC) right (↑ED50), surmountable by ↑agonist.
• Non-competitive antagonists reduce Emax (↓Emax) and are typically insurmountable.